Korea's Lunit and Agilent Technologies announced a nonexclusive collaboration to develop AI-based companion diagnostic (CDx) solutions, combining Lunit’s AI with Agilent’s tissue-based CDx expertise to address novel and complex biomarker assays in drug development, according to Lunit on Monday.

Under the agreement, the companies will co-develop AI-powered tools to enhance diagnostic accuracy and measure therapeutic efficacy, initially pairing Lunit’s algorithms with Agilent’s assays to evaluate biomarkers critical for new therapies.

The joint solutions are intended to support pharma CDx development and improve the precision and accuracy of biomarker testing.